Associations - PD1 inhibitor

SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression	Lung Cancer	SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression	Lung Cancer	pembrolizumab Resistant: C4 – Case Studies IASLC-TTLC 2023 - 6 days (New C4) pembrolizumab Resistant : C4 IASLC-TTLC 2023 - 6d	pembrolizumab Resistant: C4 – Case Studies IASLC-TTLC 2023 - 6 days pembrolizumab Resistant : C4 IASLC-TTLC 2023 - 6 days - (New C4)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval FDA - 1 week (New A1) pembrolizumab Sensitive : A1 FDA - 1wk	pembrolizumab Sensitive: A1 - Approval FDA - 1 week pembrolizumab Sensitive : A1 FDA - 1 week - (New A1)
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week (New A1) pembrolizumab Sensitive : A1 Pharmabiz - 1wk	pembrolizumab Sensitive: A1 - Approval Pharmabiz - 1 week pembrolizumab Sensitive : A1 Pharmabiz - 1 week - (New A1)
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week (New A2) pembrolizumab Sensitive : A2 NCCN - 1wk	pembrolizumab Sensitive: A2 - Guideline NCCN - 1 week pembrolizumab Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week (New B) pembrolizumab Sensitive : B Merck (MSD) Press Release - 1wk	pembrolizumab Sensitive: B - Late Trials Merck (MSD) Press Release - 1 week pembrolizumab Sensitive : B Merck (MSD) Press Release - 1 week - (New B)
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks (New A1) serplulimab Sensitive : A1 Henlius Press Release - 2wk	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks serplulimab Sensitive : A1 Henlius Press Release - 2 weeks - (New A1)
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks (New A1) penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2wk	penpulimab Sensitive: A1 - Approval Akeso Biopharma Press Release - 2 weeks penpulimab Sensitive : A1 Akeso Biopharma Press Release - 2 weeks - (New A1)
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New B) tislelizumab Sensitive : B ASCO-GI 2023 - 2wk	tislelizumab Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks tislelizumab Sensitive : B ASCO-GI 2023 - 2 weeks - (New B)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks (New B) toripalimab Sensitive : B BioSpace - 2wk	toripalimab Sensitive: B - Late Trials BioSpace - 2 weeks toripalimab Sensitive : B BioSpace - 2 weeks - (New B)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Solid Tumor	PD-L1 expression	Solid Tumor	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab + MK-4280 Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab + MK-4280 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks camrelizumab + pyrotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + TMB-H	Solid Tumor	MSI-H/dMMR + TMB-H	Solid Tumor	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2wk	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + KMT2D mutation	Solid Tumor	MSI-H/dMMR + KMT2D mutation	Solid Tumor	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2wk	pucotenlimab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pucotenlimab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	pembrolizumab Sensitive: C4 – Case Studies BMJ Case Rep - 2 weeks (New C4) pembrolizumab Sensitive : C4 BMJ Case Rep - 2wk	pembrolizumab Sensitive: C4 – Case Studies BMJ Case Rep - 2 weeks pembrolizumab Sensitive : C4 BMJ Case Rep - 2 weeks - (New C4)
TMB-H + PD-L1 expression	Lung Cancer	TMB-H + PD-L1 expression	Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies Medicine (Baltimore) - 2 weeks (New C4) pembrolizumab Sensitive : C4 Medicine (Baltimore) - 2wk	pembrolizumab Sensitive: C4 – Case Studies Medicine (Baltimore) - 2 weeks pembrolizumab Sensitive : C4 Medicine (Baltimore) - 2 weeks - (New C4)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) nivolumab Sensitive : D ASCO-GI 2023 - 2wk	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks nivolumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) pembrolizumab Sensitive : D ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression	Non Small Cell Lung Cancer	KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression	Non Small Cell Lung Cancer	anlotinib + camrelizumab Sensitive: C4 – Case Studies Front Pharmacol - 3 weeks (New C4) anlotinib + camrelizumab Sensitive : C4 Front Pharmacol - 3wk	anlotinib + camrelizumab Sensitive: C4 – Case Studies Front Pharmacol - 3 weeks anlotinib + camrelizumab Sensitive : C4 Front Pharmacol - 3 weeks - (New C4)
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline ASCO.org - 4 weeks (New A2) pembrolizumab Sensitive : A2 ASCO.org - 4wk	pembrolizumab Sensitive: A2 - Guideline ASCO.org - 4 weeks pembrolizumab Sensitive : A2 ASCO.org - 4 weeks - (New A2)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1

PD1 inhibitor

PD1 inhibitor

Associations(1820)

Associations
(1820)